-- 周四下午晚些时候，医疗保健类股上涨，纽约证券交易所医疗保健指数上涨2.6%，道富医疗保健精选行业SPDR ETF (XLV)上涨2.3%。 iShares生物技术ETF (IBB)上涨1.9%。 公司新闻方面，UniQure (QURE)股价飙升超过16%，此前该公司表示计划在第三季度向英国提交AMT-130的上市许可申请，用于治疗亨廷顿病。 Axsome Therapeutics (AXSM)股价飙升12%，此前该公司表示，美国食品药品监督管理局(FDA)已批准Auvelity用于治疗阿尔茨海默病痴呆症相关的躁动症状。 礼来公司(LLY)上调了全年业绩预期，并公布了超出市场预期的第一季度业绩，其中Mounjaro的销售额增长超过一倍。礼来股价上涨超过10%。 美国食品药品监督管理局（FDA）提议将替泽帕肽、索玛鲁肽和利拉鲁肽从503B原料药清单中移除，理由是临床上没有必要将原料药外包给其他机构进行配制。礼来公司生产替泽帕肽，其商品名为Mounjaro，用于治疗2型糖尿病，以及Zepbound，用于治疗慢性体重管理。诺和诺德公司（Novo Nordisk，股票代码：NVO）生产索玛鲁肽，其商品名为Ozempic，用于治疗2型糖尿病，以及Wegovy，用于治疗慢性体重管理；利拉鲁肽的商品名为Victoza，用于治疗2型糖尿病，以及Saxenda，用于治疗慢性体重管理。诺和诺德的股价上涨超过5%。
Related Articles
Mining & Metals
Eldorado Gold Q1 Adjusted Net Earnings Attributable to Holders US$188.2M, or $0.95 EPS
$ELD.TO
Research
Research Alert: Lpla Q1: Beats On Eps, Misses On Revenue, As Advisory Shift Improves Margins
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:LPLA delivered Q1 2026 results, with revenues surging 35% to $5.94B (missing estimates by $60M) and adj. EPS of $5.60 beating Street estimates by $0.13. The wealth management transformation accelerated with advisory revenue reaching $2.62B (+55%) and advisory assets growing to $1.39T (+42%), now representing 59.5% of total client assets. We believe LPLA's strategic shift toward fee-based services continues creating a more stable revenue base while improving operating leverage, with total advisory and brokerage assets reaching $2.34T (+30%). Management lowered the upper end of its 2026 core G&A outlook by $20M to $2.16B-$2.19B, including Commonwealth-related expenses. The Commonwealth acquisition remains on track for Q4 2026 completion with asset retention targeting 90% and updated run-rate EBITDA of $410M. With corporate cash of $567M and leverage at 1.86x, we expect LPLA maintains substantial financial flexibility for growth initiatives and plans to resume share repurchases with an estimated $125M in Q2 2026.
$LPLA
Research
Research Alert: Team: Results And Guidance Surpass Expectations As Cloud Growth Accelerates
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:TEAM delivered a strong Q3 beat with non-GAAP EPS of $1.75 exceeding consensus by $0.41, while total revenue of $1.787B grew 32% Y/Y, surpassing expectations by $90M. Cloud revenues of $1.132B accelerated to 29% growth from 26% in Q2, while Data Center sales of $560.7M surged 44% Y/Y, reaccelerating from Q2's 20% growth. RPO growth accelerated again, up 37% Y/Y reaching $3.996B, demonstrating strengthening demand and larger customer commitments driven by its AI-powered System of Work strategy. Despite restructuring charges of $223.8M, non-GAAP operating margin expanded 800 bps Y/Y to 34%, while free cash flow of $561.3M represented a 31% margin, up from Q2's 11%. Management raised FY 26 revenue growth guidance to 24% from 22%, with operating margin guidance improving to 29% from 25.5%. We view the balanced growth across Cloud migration and Data Center expansion as positive, demonstrating TEAM's ability to optimize customer transitions while maintaining strong operational leverage.
$TEAM